Success Story

Tmunity expands Penn pact, picking up another CAR-T program, rights to manufacturing tech

Tmunity Therapeutics was born out of an extensive collaboration with the University of Pennsylvania that netted it the technology, know-how and programs it needed to go after better cell therapies for cancer. Now, the biotech is bolstering that pact, picking up a new CAR-T program and the rights to certain technologies.

Under the original partnership, Tmunity had already licensed four CAR-T programs for solid tumors from the Center for Cellular Immunotherapies (CCI) at Penn’s Perelman School of Medicine. Now, it is getting “further access and rights” to certain platform and manufacturing technologies, and it is licensing a CAR-T program that targets mesothelin, according to a statement.

Read more in Fierce BioTech

Skip to content